Key Insights

Highlights

Treatment Research

7 treatments under study, led by Cetuximab Egfr Inhibitor

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07768189Phase 3RecruitingPrimary

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07718620Not ApplicableRecruitingPrimary

HPV-associated Oropharyngeal Carcinoma (HPV-OPC)

Showing all 2 trials

Research Network

Common Treatments

  • Cetuximab Egfr Inhibitor1
  • Capcitabine1
  • Hpv P161
  • Docetaxel1
  • Crb7011

Active Sponsors

  • Masaryk Memorial Cancer Institute1
  • Corbus Pharmaceuticals Inc.1
  • CSPC Megalith Biopharmaceutical Co.,Ltd.1

Top Investigators

Activity Timeline